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tients, while proliferative retinopathy is another common 
cause  [1] . For both of these retinal complications of dia-
betes laser treatment can, if timely applied, greatly reduce 
the probability of vision loss. Of course, the other modifi-
able risk factors of disease progression have to be opti-
mized in adjunction to any laser therapy, especially opti-
mizing blood glucose control  [2, 3] and tight blood pres-
sure control  [4] .
 History of Laser Treatment 
 While H.G. Wells foresaw the development of lasers 
in his book  The War of the Worlds in 1897, it was not un-
til 1960 that Maiman built the first working laser. A 
flash of light was used to deliver light energy to a ruby 
crystal. Due to 1 totally and 1 partially reflecting mirror 
at each end a light amplification by stimulated emission 
of radiation (LASER) device is obtained. The typical 
characteristics are monochromatic light, spatial coher-
ence and a high density of electrons. Several different 
wavelengths have been and are being developed, in-
cluding ruby (694 nm), argon green (514 nm), krypton 
(647 nm), Nd:YAG (1,064 and frequency doubled to
532 nm), diode (810 nm), excimer (193 nm).
 The previously used xenon light photocoagulator had 
been developed by the German ophthalmologist Meyer-
Schwickerath together with Littmann from Zeiss in the 
1950s and made photocoagulation independent of sun-
light and weather conditions. Its spot size was variable 
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 Abstract 
 Diabetic retinopathy is a leading cause of visual impairment 
and blindness in developed countries due to macular ede-
ma and proliferative diabetic retinopathy (PDR). For both 
complications laser treatment may offer proven therapy: 
the Diabetic Retinopathy Study demonstrated that panreti-
nal scatter photocoagulation reduces the risk of severe vi-
sual loss by  1 50% in eyes with high-risk characteristics. Pan-
retinal scatter coagulation may also be beneficial in other 
PDR and severe nonproliferative diabetic retinopathy 
(NPDR) under certain conditions. For clinically significant 
macular edema the Early Treatment of Diabetic Retinopathy 
Study could show that immediate focal laser photocoagula-
tion reduces the risk of moderate visual loss by at least 50%. 
When and how to perform laser treatment is described in 
detail, offering a proven treatment for many problems as-
sociated with diabetic retinopathy based on a high evidence 
level.  Copyright © 2007 S. Karger AG, Basel 
 Introduction 
 Diabetic retinopathy is a leading cause of visual im-
pairment and blindness in developed countries. Macular 
edema is the major cause of vision loss in diabetic pa-
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ranging from 3° to 8° (i.e. minimum spot size approx. 
 1 500   m) and the burns had greater power than laser 
burns, therefore usually yielding full thickness burns. In 
contrast, the laser effects include (depending on laser 
type, tissue characteristics and settings) photochemical 
effects, photoirradiation, photocoagulation and photo-
disruption. Lasers became available for ophthalmologic 
applications in the late 1960s and became more frequent-
ly used in the 1970s. Coagulation treatment of the retina 
for diabetic retinopathy became a standard of care since 
the Diabetic Retinopathy Study (DRS) results were pub-
lished in the late 1970s. It showed a great reduction of 
severe vision loss in high-risk proliferative disease for 
both xenon and argon laser photocoagulation  [5]. 
 Panretinal Laser Treatment for Proliferative Diabetic 
Retinopathy 
 The DRS enrolled 1,742 patients, 876 of whom were 
randomized to the argon group and 875 to the xenon 
group  [6] . Argon photocoagulation involved the place-
ment of 800–1,600 burns with 500   m diameter or 500–
1,000 burns with 1,000   m diameter, both at 0.1 s of du-
ration. The areas treated included the retina to or beyond 
the vortex veins in 1 or 2 sessions, also covering neovas-
cularization of the optic disc (NVD), which is no longer 
typically performed today. The primary endpoint of the 
study was a visual acuity of  ! 5/200 on 2 consecutive vis-
its 4 months apart. After 3 years argon laser coagulation 
could decrease the rate of severe visual loss to 13.3%, and 
xenon coagulation to 18.5%, while untreated eyes had 
26.4%. Thus at least a 50% reduction in the rate of severe 
visual loss could be demonstrated for panretinal laser 
treatment, which was maintained during a 5-year fol-
low-up period  [7] . The harmful effects of photocoagula-
tion were more pronounced for xenon coagulation than 
for argon laser coagulation and included a reduction of 
visual acuity due to treatment and loss of peripheral vi-
sual field. For laser treatment a decrease by  6 1 lines oc-
curred in 10% and a mild constriction of visual fields in 
5%  [7] . Macular edema, which may be exacerbated by 
panretinal photocoagulation and will be discussed in 
detail later, was not evaluated in the DRS. Finally the so-
called high-risk characteristics, for which the benefits of 
peripheral coagulation outweigh the risks, were defined 
as  [7, 8] :
 1 NVD  6 1/4 to 1/3 disc area in extent 
 2 New vessels on or within 1 disc diameter of the optic 
disc (NVD) 
 3 Any new vessels within 1 disc diameter of the optic 
disc and associated with vitreous or preretinal hemor-
rhage 
 4 Proliferation elsewhere at least 1/2 disc area in size and 
associated with vitreous or preretinal hemorrhage 
 The risk of severe visual loss was 26% for eyes exhibit-
ing these high-risk characteristics (at least 3 of 4 signs) as 
compared to 7% in proliferative diabetic retinopathy 
(PDR) without those characteristics after 2 years  [9] . Pho-
tocoagulation reduced this risk by 50%. Therefore the 
DRS recommends panretinal laser treatment for (1) eyes 
with new vessels and preretinal or vitreous hemorrhage; 
and (2) eyes with new vessels on or within 1 disc diameter 
of the optic disc (NVD)  6 1/4 to 1/3 disc area in extent 
(with or without preretinal or vitreous hemorrhage)  [7] . 
It was not able to give recommendations on earlier stages 
such as severe nonproliferative patients.
 The current international clinical diabetic retinopathy 
disease severity scale distinguishes 5 levels of retinopathy 
 [10] : (0) no apparent retinopathy; (1) mild nonprolifera-
tive diabetic retinopathy (NPDR, only microaneurysms); 
(2) moderate NPDR; (3) severe NPDR (including any of: 
 1 20 intraretinal hemorrhages in each quadrant, venous 
beading in  6 2 quadrants, intra-retinal microvascular 
abnormalities (IRMA) in  6 1 quadrant, but no prolifera-
tions), and (4) proliferative retinopathy (defined by neo-
vascularization and/or vitreous/preretinal hemorrhage). 
The subgroup with high-risk characteristics has been de-
scribed by the DRS above.
 A summary of current treatment recommendations 
for laser therapy using this disease scale  [11–13] is given 
in  figure 1 . In supplementation to the DRS criteria it is 
recommended at a high evidence level  [9] to perform 
panretinal laser coagulation for PDR, NVD, prolifera-
tion elsewhere  1 1/2 disc area, vitreous/preretinal hem-
orrhage and neovascularization of the iris under certain 
conditions. Additionally, for severe NPDR scatter laser 
coagulation may be indicated in some cases (see  fig. 1 ). 
Laser treatment should be performed over a period of 
4–6 weeks at 500   m spot size, spaced 0.5 burn widths 
from each other with 0.1–0.2 s of duration (for green la-
sers). Intensity should be regulated so that mild white 
bleaching is obtained, the treatment area reaches from 
the temporal arcade to the equator and up to 2 disc di-
ameters temporal from the macular center. Around the 
optic disc some space (e.g. 1 disc diameter) should be 
spared (see  fig. 2 ) to avoid central visual field defects 
 [14] .
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 Laser Treatment of Macular Edema 
 Macular edema is responsible for a major part of vi-
sual impairment associated with diabetic retinopathy  [1] . 
Correct and timely treatment is of vital importance to 
avoid severe visual loss. The Early Treatment of Diabetic 
Retinopathy Study (ETDRS) formed the basis of current 
treatment regimens by laser. The multicenter random-
ized study was designed to investigate the effect of pho-
tocoagulation and aspirin treatment in patients with 
(0) No Retinopathy 
(1) Mild NPDR
(2) Moderate NPDR
(3) Severe NPDR
(4) PDR
Observe
Yes
High Risk
Characteristics 
No
No
Yes
• poor compliance with follow-up
• impending cataract extraction
• impending pregnancy
• status of the fellow eye
• type1/2 diabetes
Scatter (Panretinal) Laser Coagulation
 Fig. 1. Algorithm for panretinal scatter co-
agulation of the retina  [11–13] . For details 
of the used classification see text. A macu-
lar edema must be assessed separately (see 
text and fig. 2). Type 2 diabetes (older pa-
tients) may benefit more from early scatter 
photocoagulation  [60] .  
 Fig. 2. Illustration of treatment area for 
panretinal scatter photocoagulation on 
widefield imaging (Optomap, Optos, Dun-
fermline, Fife, Scotland, UK). For details 
please see text. 
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NPDR and early proliferative retinopathy. It enrolled a 
total of 3,711 patients between 1980 and 1985 who met the 
following criteria: (1) no macular edema with visual acu-
ity  1 20/40 and (2) macular edema with visual acuity 
 1 20/200.
 As one result the ETDRS showed that the randomized 
intake of 650 mg aspirin per day did not alter the clinical 
course  [15] . It also investigated as a second question when 
in the course of diabetic retinopathy panretinal laser co-
agulation is most effective. To answer both these ques-
tions, patients without macular edema were randomized 
to either early (mild or full) scatter photocoagulation or 
deferral. Eyes with macular edema were randomized to 
either deferral or immediate focal or immediate panreti-
nal plus follow-up focal photocoagulation. Full scatter 
photocoagulation was defined as in the DRS, and mild 
scatter photocoagulation consisted of 500-  m spots 
spaced 1 burn width apart from each other. For eyes with-
out macular edema, no benefit resulted from immediate 
photocoagulation (either mild or full scatter, focal where 
needed) to prevent moderate or severe visual loss. For 
eyes with macular edema and more severe retinopathy a 
small reduction of the risk for severe visual loss was found 
with early photocoagulation  [16] . However, there was an 
increased risk of moderate visual loss in the treatment 
group after 6 weeks, which after 1 year reversed. The least 
visual loss was in the group treated by mild scatter to-
gether with immediate focal photocoagulation  [16] . This 
supports the algorithm given in  figures 1 and  3 regarding 
timing of scatter photocoagulation and further justifies 
photocoagulation in non-high-risk characteristic eyes 
 [16] .
 The third and main question to be answered by the 
ETDRS was the efficacy of laser treatment for macular 
edema ( fig. 3 ). Macular edema was defined as: (1) thick-
ening of the retina at or within 500   m of the center of 
the macula; (2) hard exudates at or within 500   m of the 
center of the macula, if associated with thickening of ad-
jacent retina, and (3) a zone of retinal thickening  6 1 disc 
area, any part of which is within 1 disc diameter of the 
center of the macula.
 Any of these 3 criteria defined clinically significant 
macular edema (CSME, see  fig. 4 ). Focal laser treatment 
consisted of 50- to 100-  m laser burns of 0.05–0.1 s dura-
tion directed at microaneurysms between 500 and 3,000 
  m from the macular center achieving whitening around 
or (if   1 40   m) color change of the microaneurysm. Treat-
ment closer than 300   m from the fovea was not recom-
mended (rarely  ! 500   m). Diffuse leakage or nonperfu-
sion were treated in a more indirect way focused at the 
retinal pigment epithelium: within 2 disc areas of the fo-
vea a grid pattern with 50- to 200-  m spots, spaced 1 
burn width apart, was applied  [17] .  Figure 4 illustrates the 
size relationships. Moderate visual loss, defined as  1 15 
Focal Laser
Coagulation 
Observe
Yes
CSME
No
Exclude Ischemia
Focal edema
Yes
Yes
No
No, diffuse
No Macular Edema Macular Edema
(Levels: Mild, moderate, severe)
No Focal Laser
Coagulation
(consider other
treatment modalities) 
Grid Laser Coagulation
(option for visual acuity >20/200;
consider other treatment modalities) 
 Fig. 3. Algorithm for laser treatment for 
macular edema. Please note that prolifera-
tive disease must be assessed separately as 
discussed in the text and shown in figure 
1. CSME = clinically significant macular 
edema. 
 Laser Treatment in Diabetic Retinopathy Ophthalmologica 2007;221:95–102 99
letters (i.e.  6 3 lines), was the primary endpoint. In brief, 
the ETDRS could show that immediate focal laser coagu-
lation in eyes with CSME could reduce the percentage of 
eyes with moderate visual loss by at least 50%. This effect 
was maintained over follow-up time, for example after 3 
years 12% as opposed to untreated 24% was achieved  [16] . 
However, visual improvement was observed in a minor-
ity of cases; for the majority of cases the goal of photoco-
agulation is to stabilize visual acuity. Therefore patients 
with good visual acuity and CSME should definitely be 
considered for treatment  [18] . On average 3–4 treatment 
sessions 2–4 months apart were needed  [19] . The side ef-
fects of focal photocoagulation include an initial decrease 
in central vision and rarely subretinal fibrosis with cho-
roidal neovascularization. The development of subretinal 
fibrosis is associated with the degree of subretinal exu-
dates and only 8% were directly attributable to laser co-
agulation  [20] . Paracentral scotomas may be noted by the 
patient with burns close to the macular center, especially 
when confluent  [21] .
 Diffuse Macular Edema 
 In focal macular edema well-defined focal areas of 
leakage with retinal thickening are seen. As described 
above for the ETDRS, treatment may consist of either di-
rect treatment of leaking microaneurysms or indirect 
treatment of the retinal pigment epithelium, usually ap-
plied in a more grid-like fashion directed towards thick-
ened areas. In contrast, in diffuse macular edema, leak-
age occurs diffusely from the retinal capillaries. Retinal 
microaneurysms, hard exudates and retinal hemorrhages 
tend to be few in number and small in size. Subtypes in-
clude central diffuse edema caused by leakage of the cap-
illaries immediately adjacent to the foveal arcade and 
generalized diffuse edema  [22] . In the latter a more wide-
spread retinal thickening is observed across the posterior 
pole. Laser treatment has been evaluated using 100- to 
200-  m spot size and just threshold burns at the level of 
the pigment epithelium. Usually spots are applied spaced 
1 spot size apart and 100–200 burns are required. The so-
called ‘grid’ pattern depends on the pattern of leakage 
and may be performed circularly around the macular 
center (including the papillomacular bundle). Visual 
acuity  ! 20/200 (0.1) is a contraindication for grid laser 
treatment  [11, 12] . The results of such treatment are con-
tradictory  [23, 24] and not of high evidence. Other treat-
ment modalities such as pars plana vitrectomy  [25] or 
different medical treatment options  [26, 27] may be more 
promising.
 Ischemic Macular Edema 
 While the accompanying edema may be variable, cen-
tral ischemia is characterized by a loss of foveal capillar-
ies/capillary nonperfusion. The clinical diagnosis is dif-
ficult, while fluorescein angiography shows an enlarged 
foveal avascular zone (i.e.  1 500   m diameter)  [12, 28, 29] . 
An example is shown in  figure 5 . Laser therapy should 
not be applied if significant ischemia exists  [22] . The 
complete algorithm for laser treatment of macular edema 
is given in  figure 3 .
 Coexistent Macular Edema and Proliferative Disease 
 When scatter photocoagulation is to be carried out in 
eyes with coexisting CSME, there is evidence that first 
performing focal laser treatment may be beneficial. Both 
the DRS and ETDRS showed that full scatter photoco-
agulation may exacerbate macular edema leading to 
moderate visual loss  [16] . This effect was quantified later 
 [30] . The ETDRS could also show some advantage for im-
mediate focal as compared to delayed focal coagulation 
together with panretinal laser therapy. Therefore it is ad-
visable to first perform focal before panretinal photoco-
agulation. In cases with high-risk PDR simultaneous fo-
cal and scatter photocoagulation should be performed 
 [11, 13] .
 Fig. 4. Illustration of treatment area for focal (and grid) photoco-
agulation for CSME. For details please see text and figure 3. 
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 Cataracts 
 Various studies suggest that diabetic retinopathy, es-
pecially macular edema, may progress following cataract 
surgery  [9, 31, 32] . Therefore, if the ocular media are clear 
enough, necessary laser therapy should be performed 
preoperatively. If this is impossible due to media opaci-
ties, re-evaluation and necessary therapy should be per-
formed as soon as possible  [11] . Regarding the implanted 
intraocular lens it is important to choose a model with a 
large optical zone facilitating further photocoagulation. 
Silicone material should definitely be avoided, since in 
the case of vitrectomy, especially with silicone oil, pre-
cipitates will occur  [33] .
 Laser Therapy for Subhyaloidal Hemorrhage 
 In case of dense subhyaloidal hemorrhage located at 
the macular center disrupting the inner limiting mem-
brane by an Nd:YAG laser  [34] or green laser  [35] may 
allow the blood to dissolve in the vitreous and be ab-
sorbed much faster. Panretinal laser treatment should be 
performed beforehand to avoid unnecessary delays. Com-
plications of the method include macular hole formation 
and retinal detachment  [36] . Other treatment options 
such as vitrectomy should also be considered in such 
 cases.
 Diode Laser Treatment 
 The diode laser is widespread due to its ease of main-
tenance, small size and lower costs. Due to its wavelength 
of 810 nm the biologic properties are different from other 
wavelengths such as the green lasers. Especially more 
profound effects of the diode laser in the choroid are 
known, which may be more painful for the patient during 
application. Regarding the effectiveness of avoiding pro-
gression of PDR no differences exist  [37, 38] . On the oth-
er hand functional parameters such as color contrast sen-
sitivity or pattern electroretinograms after panretinal 
photocoagulation may be more in favor of diode laser 
treatment  [39] , while expansion of laser spots over time 
appears to be more likely with the longer wavelength of 
the diode laser  [40] .
 Regarding macular edema, gentle threshold diode la-
ser coagulation is suitable for focal laser therapy  [41] , al-
though some studies suggest that it may be to some de-
gree less effective than green laser wavelengths  [42] . Sub-
threshold treatment minimizes damage but is to some 
extent less effective in promoting resolution of edema, 
though the difference was not significant  [43] . Micro-
pulsed application of subthreshold diode laser burns may 
increase its effectiveness  [44, 45] .
 Objective Retinal Thickness Measurements 
 While the ETDRS used stereoscopic clinical examina-
tion and stereo fundus photographs to define macular 
changes  [46, 47] , over the last decade much more sensitive 
methods have become available to quantify retinal thick-
ness objectively. Optical coherence tomography (OCT, 
Carl Zeiss Meditec, Jena, Germany) has rapidly become 
a standard method of analyzing macular changes  [48] of-
fering high resolution cross-section images. OCT and an-
other instrument, the retinal thickness analyzer (Talia 
Technology, Neve-Ilan, Israel) having less resolution, can 
reliably detect small increases of retinal thickness of at 
least 20–40   m  [49–51] . Stereoscopic fundus examina-
tion usually only detects retinal thickening of approxi-
mately 100   m  [52] . The new objective methods have 
been shown to be superior to clinical examination for in-
vestigating the extent of diabetic macular edema  [53, 54] . 
By these means it could also be shown that non-clini-
cally significant retinal thickening occurs in most dia-
betic patients even in the absence of visible retinopathy 
 [55] . This raises the question whether treatment of non-
clinically significant (‘subclinical’) macular edema may 
 Fig. 5. Illustration of severe macular capillary dropout, i.e. macu-
lar ischemia. Focal laser coagulation should be avoided in such 
cases. 
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be indicated under certain conditions – no such groups 
had been identified with the methods used in the ETDRS 
 [16] . On the other hand methods like OCT and retinal 
thickness analyzer offer sensitive tools to follow changes 
in retinal thickness objectively, which allows better as-
sessment of treatment success of e.g. focal laser treatment. 
The OCT can also identify membranes and vitreomacu-
lar traction  [56, 57] , cases in which pars plana vitrectomy 
might be more beneficial than other treatment modalities 
 [25, 58, 59] .
 Conclusions 
 Laser therapy remains the main treatment modality 
for diabetic retinopathy. The DRS demonstrated that 
panretinal scatter photocoagulation reduced the risk of 
severe visual loss by  1 50% in eyes with high-risk charac-
teristics. It may also be beneficial in other PDR and severe 
NPDR under certain conditions. The ETDRS could show 
that immediate focal laser photocoagulation reduced the 
risk of moderate visual loss for CSME by at least 50%. 
Usually several treatment sessions are required. In cases 
of both PDR and CSME, first the macula should be ad-
dressed unless high-risk characteristics warrant simulta-
neous panretinal treatment.
 In summary, laser treatment offers proven treatments 
for many problems associated with diabetic retinopathy 
at a high evidence level. However, for certain situations 
such as macular ischemia, tractive components, severe 
proliferations and maybe diffuse macular edema other 
treatment modalities may be more beneficial. Surgery is 
definitely indicated for some situations and recently 
emerging medical therapies offer a variety of new ap-
proaches, which alone or in adjunction with laser therapy 
may help to further improve the outcome of treating dia-
betic retinopathy. However, their value still has to be 
proven at the same high level of evidence as that which 
exists for laser therapy.
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